Published in Cancers (Basel), 13(20), p. 5089.
The use of neoadjuvant therapy (NAT) in patients with pancreatic ductal adenocarcinoma (PDAC) is increasing. Objective quantification of the histopathological response to NAT may be used to guide adjuvant treatment and compare the efficacy of neoadjuvant regimens. However, current tumor response scoring (TRS) systems suffer from interobserver variability, originating from subjective definitions, the sometimes challenging histology, and response heterogeneity throughout the tumor bed. This study investigates if artificial intelligence-based segmentation of residual tumor burden in histopathology of PDAC after NAT may offer a more objective and reproducible TRS solution.
Janssen, B.V., Theijse, R., van Roessel, S., de Ruiter, R., Berkel, A., Huiskens, J., Busch, O.R., Wilmink J.W., Kazemier, G., Valkema, P., Farina, A., Verheij, J., de Boer, O.J., Besselink, M.G. (2021), Cancers (Basel), 13(20), p. 5089.
Read this publication and more online on ourScientific Publications page on sas.com.
At SAS, we take big ideas that shape the future and make them bigger. On these pages we've collected the best examples of analytical and technology research at SAS, with a spotlight on the talented people that make it possible.
SAS doesn't settle for ordinary innovation. We put thought and research into ideas that matter – and then create analytics solutions that improve business and society.
Work with us. Visit sas.com/careers to find R&D opportunities at SAS.
Read more stories at the Data Science Resource Hub
More science and SAS: SAS authors who contribute to Health & Life Science research, and use of SAS software in scientific research.